Sep 14, 2025
1:00 PM2:00 PM
Poster Session
P504 - THE EFFECT OF PARENTERAL OMEGA-3 FATTY ACID ON INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE: A SYSTEMATIC REVIEW
P504
THE EFFECT OF PARENTERAL OMEGA-3 FATTY ACID ON INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE: A SYSTEMATIC REVIEW
Y. Y. Kristian1,2,*, F. N. E. Pratiwy2,3, A. A. Rachmayanti2,4, S. L. Sani2,5, Y. P. Pramesti2,3, Y. Wulandari1,4, D. Sunardi1,4
1Department of Nutrition, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, 2University College London, London, United Kingdom, 3Faculty of Medicine, Public Health and Nursing, Universitas Gajah Mada, Yogyakarta, 4Dr Cipto Mangunkusumo Hospital, 5Faculty of Public Health, Universitas Indonesia, Jakarta, Indonesia
Rationale: Patients with intestinal failure (IF) receiving long-term parenteral nutrition often develop intestinal failure-associated liver disease (IFALD). This systematic review aims to evaluate the effect of omega-3 fatty acid-containing parenteral nutrition (n-3 PN) in preventing and reversing IFALD in children and adults.
Methods: A systematic search was conducted in Embase, Medline, Global Health, and APA PsycInfo from inception until 20 February 2025. We included randomised clinical trials (RCTs), cohorts, and cross-sectionals involving children and adults with IF or IFALD who received n-3 PN. The primary outcomes included liver function, lipid profile, and inflammatory biomarkers. Five independent reviewers screened the articles, extracted data, and assessed study quality based on the Quality Criteria Checklist. This systematic review is registered with PROSPERO (ID: CRD420251000150) and follows the PRISMA guidelines.
Results: Of 1,277 articles, 12 studies (3 RCTs, 8 cohorts, 1 cross-sectional) were included, involving 214 children and 366 adults. In paediatrics (n=5 studies), n-3 PN significantly reduced direct bilirubin levels and accelerated cholestasis resolution (4.8–6.8x faster vs. soybean-based lipids). Adults demonstrated similar trends, alongside improvement in lipid peroxidation markers and antioxidant status, albeit IFALD incidence remained unchanged in one RCT. However, these beneficial effects were inconsistent in children and adults without pre-existing IFALD. Safety profiles were favourable, with no serious adverse events observed. Most of these studies had neutral to positive quality ratings.
Conclusion: N-3 PN might improve liver outcomes in children and adults with pre-existing IFALD. However, the available studies for patients without pre-existing IFALD are limited. Further high-quality RCTs are needed in both populations.
Disclosure of Interest: None declared